EXPERIENCE OF PERSONALIZED APPOINTMENT OF NEOADJUVANT CHEMOTHERAPY FOR PATIENT WITH BREAST CANCER: A PROSPECTIVE STUDY
- Authors: Slonimskaya E.M1,2, Kazantseva P.V1, Litviakov N.V1, Tsyganov M.M1, Ibragimova M.K1,3, Doroshenko A.V1, Vernadsky R.U1, Vostrikova M.A2, Lushnikova N.A2
-
Affiliations:
- Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
- Siberian State Medical University
- National Research Tomsk State University
- Issue: No 7 (2018)
- Pages: 64-70
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295476
- ID: 295476
Cite item
Abstract
Full Text
About the authors
E. M Slonimskaya
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University
Email: slonimskaya@rambler.ru
MD, Prof., Head of the Department of General Oncology
P. V Kazantseva
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
N. V Litviakov
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
M. M Tsyganov
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
M. K Ibragimova
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences; National Research Tomsk State University
A. V Doroshenko
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
R. U Vernadsky
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
M. A Vostrikova
Siberian State Medical University
N. A Lushnikova
Siberian State Medical University
References
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C., Allen C., Barber R.M., et al. Regional and national cancer incidence mortality years of life losT., years lived with disability, and disability adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-72. doi: 10.1001/jamaoncol.2016.5688.
- Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2014 году (заболеваемость и смертность). М., 2016. 250 с.
- Gnant M., Herbeck N., Thomssen Ch. St. Gallen/ Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care. 2017;12:102-7. doi: 10.1159/000475698.
- Семиглазов В.Ф. Многоликая биология рака молочной железы: поиски адекватного лечения. Злокачественные опухоли. 2016;3:5-10.
- Sikov W.M., Berty D.A., Perou C.M., et al. impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage ii to iii triple-negative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 2015;33(1):13-21. doi: 10.1200/JC0.2014.57.0572.
- Yu K., Sang Q.A., Lung P.Y., et al. Personalized chemotherapy selection for breast cancer using gene expression profiles. Sci. Rep. 2017;7:43294. doi: 10.1038/srep43294.
- Rao S., Beckman R.A., Riazi S., et al. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget. 2017;8(23):37923-34. Doi: https://doi.org/10.18632/oncotarget.13544
- Gillet J.Р., Gottesman M.M. Overcoming multidrug esistance in cancer: 35 years after the discovery of ABCB1. Drug Resist. Updat. 2012;15(1-2):2-4. doi: 10.1016/j.drup.2012.03.001.
- Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M., et al. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Oncotarget. 2016;7(7):7829-41. doi: 10.18632/oncotarget.6953
- Литвяков, Н.В., Цыганов, М.М., ЧердынцевА., Н.В. и др. Микроматричный анализ аномалий числа копий ДНК опухоли молочной железы: связь с эффектом неоадъювантной химиотерапии. Сибирский онкологический журнал. 2014;3:19-
- Юмов Е.Л., Цыганов М.М., Литвяков Н.В. и др. Экспрессия генов множественной лекарственной устойчивости и монорезистентности при немелкоклеточном раке легкого. Сибирский онкологический журнал. 2014;1:16-22.
- Казанцева П. В., Цыганов М.М., Слонимская Е.М. и др. Молекулярно-генетические маркеры эффективности неоадъювантной химиотерапии с применениемантрациклиновубольныхракоммо-лочной железы. Сибирский онкологический журнал. 2016;3:29-35.
- Nikolényi A., Sükösd F., Kaizer L., et al. Tumor topoisomerase ii alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology. 2011;80(3-4:269-77. doi: 10.1159/000329038.
- Susini T., Berti B., Carriero C., et al. Topoisomerase ii alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. Onco. Targets Ther. 2013;7:2111-20. Doi: https://doi. org/10.2147/OTT.S71646
- Brouckaert O., Wildiers H., Floris G., Neven P. Update on triple-negative breast cancer: prognosis and management strategies. int. J. Womens Health. 2012;4:511-21. doi: 10.2147/iJWH.S18541.
- Liu Y., Li Q., Zhou L., et al. Cancer drug resistance: redox resetting renders a way. Oncotarget. 2016;7(27):42740-61. Doi: 10.18632/ oncotarget.8600.
- Byrski T., Huzarski T., Dent R., et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Сancer Res. Treat. 2014;147(2):401-5. doi: 10.1007/s10549-014-3100-x.
- Kriege M., Jager A., Hooning M.J., et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 2012;118(4):899-907. Doi: 10.1002/ cncr.26351.
- Karki R., Mariani M., Andreoli M., et al. ßiii-Tubulin: biomarker of taxane resistance or drug target? Expert Opin. Ther. Targets. 2013;17(4):461-72. doi: 10.1517/14728222.2013.766170.
- Wikman H., Westphal L., Schmid F., et al. Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget. 2014;5(10):3076-87. Doi: https://doi.org/10.18632/oncotarget.1832